Global Initiative for the Elimination of Avoidable Blindness

WORLD HEALTH ORGANIZATION
Prevention of Blindness and Deafness

VISION 2020
THE RIGHT TO SIGHT
Global Initiative

for the Elimination

of Avoidable Blindness
Acknowledgement

This document was prepared through a series of workshops conducted by the World Health Organization's Programme for the Prevention of Blindness and Deafness in collaboration with the Task Force of the Partnership Committee of Nongovernmental Organizations dedicated to the Prevention of Blindness and the Education and Rehabilitation of the Blind.

*World Health Organization, 1997

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors.
# CONTENTS

**Section 1**
Overview of the present global blindness situation and future trends

1.1 Present magnitude and major causes of visual impairment .................................................. 1
1.2 Trends and future projections ............................................................................................... 2
1.3 Benefits and costs of blindness prevention ........................................................................... 3
1.4 Why a 25-year global plan? .................................................................................................. 4
1.5 Mobilization of resources .................................................................................................... 5
1.6 Interaction and coordination between interested parties ..................................................... 6

**Section 2**
Outline of main activities within a
Global Initiative for the Elimination of Avoidable Blindness

Introduction ................................................................................................................................ 8

2.1 Control of major causes of blindness

   Cataract ................................................................................................................................. 8
   Trachoma .............................................................................................................................. 14
   Onchocerciasis ...................................................................................................................... 16
   Childhood blindness ............................................................................................................. 17

   Vitamin A deficiency .......................................................................................................... 18
   Surgically avoidable causes ............................................................................................... 19

   Refractive errors and low vision ......................................................................................... 20
2.2 Human resource development

Community level ....................................................... 22
Secondary and tertiary levels ...................................... 24

2.3 Infrastructure and appropriate technology development

Infrastructure .......................................................... 28
Technology ............................................................. 30

Section 3
Structure and work plan development
for the Global Initiative for the Elimination of Avoidable Blindness

Introduction ........................................................... 32

3.1 Structure for the Global Initiative ................................ 32
3.2 Phases of implementation ........................................ 33
3.3 Monitoring and evaluation ........................................ 34

Annex 1. Benefits and costs of blindness prevention initiatives .................................................. 37
Annex 2. Control of other causes of blindness ................................................................. 45
Preamble

- This document has been produced following consultations held in Geneva during 1996 and 1997, convened by the WHO Programme for the Prevention of Blindness and Deafness (PBD) at the request of, and with support from, the Task Force of the Partnership Committee of Nongovernmental Development Organizations.

- The purpose of these meetings was to initiate the development of a global plan to enable all parties and individuals involved in combating blindness to work in a focused and coordinated way to achieve the common goal of eliminating all avoidable blindness.

- The document outlines objectives, strategies, indicators and targets for service delivery of eye care, in order to eliminate blindness from the five most amenable causes of avoidable blindness at the present time. Information is also given on strategies for the control of other significant causes of blindness.

- The document does not attempt to address research priorities and is not comprehensive for all causes of visual loss and blindness.
Section 1

Overview of the present global blindness situation
and future trends

1.1 PRESENT MAGNITUDE AND MAJOR CAUSES OF VISUAL IMPAIRMENT

An analysis of the available data on blindness and low vision, through the PBD Data Bank, points to the following situation analysis:

- There are nearly 38 million blind people and almost 110 million with low vision, giving a total of nearly 150 million people with some degree of visual impairment.¹

- There are 8.9 million blind people in India, 6.7 million in China and 7.1 million in Africa - together this constitutes nearly 60% of the global burden of blindness.

- The major cause of blindness in India, China and sub-Saharan Africa is cataract. Globally there are at least 16 million people who are blind from cataract.

- Trachoma is the second cause of blindness in sub-Saharan Africa, China and the Middle-Eastern countries, with a global estimate of 5.9 million people being blind from trachoma.

- Glaucoma occurs in all parts of the world, but different types of glaucoma are seen in different regions. It is estimated that 5.2 million people are blind from glaucoma.

- Onchocerciasis is an important cause of blindness in endemic foci in West and Central Africa, being responsible for 0.3 million blind people.

- Other causes of blindness, particularly diseases of the posterior segment of the eye, account for more than 10 million blind people.

- The prevalence of blindness increases from 0.08% in children to 4.4% in people aged over 60 years, with an overall global prevalence of 0.7%.

- There are no good available data on the incidence of blindness, although it is estimated that at least 7 million people become blind each year and that the number of blind people worldwide is at present increasing by 1-2 million per year.

It should be noted that, although there are limited population-based data from some regions of the world, the available data are sufficient to enable a strategic plan to be developed and confirm that:

- the age-specific prevalence of blindness in most parts of the developing world is several times greater than that in the economically developed world;

¹ These figures are based on the 1990 global population. If the 1996 population situation were applied, there would be a projected number of 45 million blind and 135 million people with low vision.
• two-thirds or more of all blindness is avoidable, in that the causes are preventable or treatable;

• unoperated cataract has been shown to be the major cause of blindness, accounting for 40%-80% of all causes of blindness in the available population-based surveys.

1.2 TRENDS AND FUTURE PROJECTIONS

Data on projected global trends over the next 25 years, with regard to demographic, economic and health care situations, have been used by the PBD secretariat to assess trends and to make some future projections.

• During the last 20 years, there has been an economic crisis which has affected the least developed countries in a particularly negative manner, resulting in greater unemployment and reduced governmental revenue for health expenditure.

• The global population will increase from 5.8 billion in 1996 to an estimated 7.9 billion by 2020; most of this increase will take place in the developing world.

• The global population is ageing, with an estimated 1 billion people aged over 45 years in 1996, increasing to 2 billion by 2020.

• There is increasing urbanization, with 45% of the global population now living in cities, which will increase to 60% by 2020. This urbanization, which particularly affects cities in the developing world, is due mainly to an internal migration of young people and leaves rural areas increasingly marginalized.

• The ageing population is resulting in an increase in noncommunicable chronic diseases.

• At present the Disability-Adjusted Life Years (DALYs) are more or less equally distributed between communicable and noncommunicable diseases, but over the next 20 years it is projected that the proportion of DALYs due to noncommunicable diseases will increase.

• An analysis of interventions over the last 10-20 years in five countries has shown a decrease in the prevalence of blindness in some communities, but an increase in others. It is, however, difficult to draw any definite conclusions from the limited data.

• Governments are increasingly looking to consumers of health care to pay for health services and treatment, while consumers, who have increasing expectations, are seeking hospital as opposed to primary care, having the perception that hospital care is of better quality than primary care.

• There is generally a reduction in available funds for blindness prevention from the governments of developing countries, due to a combination of economic recession and new competing demands for the limited resources.
1.3 BENEFITS AND COSTS OF BLINDNESS PREVENTION

Blindness has profound human and socioeconomic consequences in all societies. The costs of lost productivity, and rehabilitation and education of the blind, constitute a significant economic burden, particularly in many developing countries. Furthermore, blindness is often associated with lower life expectancy in such settings; thus, the prevention and cure of blindness can provide enormous savings and facilitate societal developments.

In its World Development Report in 1993, the World Bank developed the concept of “Disability-Adjusted Life Years” (DALYs), which is a composite measure of the time lived with a disability, together with the time lost due to premature mortality. The “DALY” measure allows for a comparative assessment of health care interventions in terms of cost per DALY saved. Although this measure is not perfect, and sometimes criticized, it is increasingly used as a tool for comparative assessment of cost-utility.

**Cataract** is by far the major cause of easily curable blindness worldwide. As there are no known effective means of preventing the most common forms of cataract, all efforts have to be made to provide surgery to all those in need. Cataract surgery can be one of the most cost-effective of all health interventions, with a cost per DALY saved in the order of US$ 20-40. In fact, good-quality, high-volume cataract surgery can be provided at less than US$ 10 per DALY in some settings. Cataract interventions are thus as cost-effective as immunization and can have a very significant and rapid impact in reducing the burden of avoidable blindness in a population.

**Onchocerciasis** is being successfully brought under control in West Africa through the Onchocerciasis Control Programme (OCP). Eleven countries in West Africa have got rid of the disease as a public health problem, implying more than 600 000 cases of blindness prevented, some five million years of productive labour added with 25 million hectares of land freed up. The overall success of OCP has been analysed in economic terms and shown to give a highly satisfactory Economic Return Rate of 20%; this is a measure of the total economic benefits of the Programme, compared to total costs. Almost equally advantageous, the new African Programme for Onchocerciasis Control (APOC), covering the remaining 19 endemic countries in Africa, will yield an Economic Return Rate of 18%.

**Trachoma** is a disease requiring a range of medical, behavioural and environmental interventions. Available data from some endemic countries have shown that both non-surgical (education and antibiotics) and surgical interventions (lid surgery for trichiasis) for trachoma control share with cataract surgery the distinction of being among the most cost-effective blindness prevention measures.

In the field of childhood blindness, the control of xerophthalmia has been shown to be particularly cost-effective. The mass distribution of vitamin A capsules at semi-annual intervals is one of the highest ranked of all health interventions available, yielding a cost per DALY saved of only US$ 9. The comparable cost for vitamin A fortification would be around US$ 29 per DALY.

Some preliminary analysis recently undertaken suggests that the direct economic cost of the global burden of blindness is US$ 25 billion: this figure may double, or triple, if indirect costs are also considered. Given the cost-effective interventions available to prevent or cure blindness, as described above, there is every reason to consider blindness prevention as one of the most worthwhile public health and developmental interventions that can be undertaken.

*See further Annex 1.*
1.4 WHY A 25-YEAR GLOBAL PLAN?

1.4.1 Reasons for a global plan

A global plan is important for the following reasons:

(a) It allows priorities to be defined and appropriate effective and efficient strategies to be determined and then implemented, including appropriate long-term research strategies.

(b) It can be used for advocacy and resource mobilization, as all partners can use the global plan to raise new funds and to develop prevention of blindness activities.

(c) It facilitates the coordination and development of work by the different partners involved in prevention of blindness.

(d) It encourages the building of new partnerships between the government, private, corporate and voluntary sectors in society.

(e) It allows the evaluation of activities, in order to learn from experience, as targets and objectives for the programme have been defined.

1.4.2 Available coordination mechanisms

At present, prevention of blindness activities are coordinated through a number of different mechanisms. These include the following:

(a) The WHO Programme Advisory Group, which meets every two years to advise on the WHO Programme’s development, including its collaboration with NGDOs and identified collaborating centres.

(b) Annual meetings of NGDOs with WHO/PBD in the Partnership Committee, and quarterly meetings with the Task Force of NGDOs to initiate new activities.

(c) The WHO collaborating centres for the prevention of blindness involved in training and research for blindness prevention, on a joint work plan basis with each institution.

(d) Direct official relations between some NGDOs and WHO, implying a joint workplan agreement on a regular three-year basis. This is of particular importance for human resource development at all levels of health care. In many settings, ophthalmologists will play a key role as national coordinators or in initiating specific activities, mainly for training or provision of eye care, including common surgery, for example for cataract. The International Federation of Ophthalmological Societies, through its executive branch, the International Council of Ophthalmology, maintains close relations with the WHO Programme for this purpose. Other cadres of eye care personnel are also important in national programme developments, such as ophthalmic medical assistants, nurses or clinical officers, optometrists, opticians, etc., as applicable in each specific country situation (see section 2.2).

(e) Specific programmes, including SightFirst, trachoma control and ivermectin distribution.
1.4.3 Development of work

The **WHO collaborating centres** have an important role to play in prevention of blindness through:

(a) **appropriate operational research**, which can make the use of existing resources more effective and efficient;

(b) **technical consultancy** to multilateral agencies, national programmes for the prevention of blindness and NGDOs;

(c) the provision of **training** for eye care professionals in prevention of blindness and particularly in community ophthalmology;

(d) conducting **evaluations** of blindness prevention activities and projects, at the request of other interested parties.

1.4.4 Partnership development

The International Agency for the Prevention of Blindness (IAPB) functions as an umbrella organization which has played an important role in promoting prevention of blindness globally and continues to have an essential **coordinating and advocacy** role. IAPB brings together the human resources of the International Federation of Ophthalmological Societies and the financial resources of the NGDOs, which can result in programme activity, in accordance with WHO/PBD technical strategies, through the national committees of blindness prevention in Member States. The development of regional workshops over the last eight years has been successful in bringing together interested parties to look at priorities and strategies for controlling blindness at the regional level. These workshops could be further developed and used as an instrument for promoting the global plan, establishing regional initiatives and strengthening national programmes.

1.5 MOBILIZATION OF RESOURCES

Funding for prevention of blindness activities can be generated from a number of different sources. These include the following:

(a) **Cost-recovery from patients**

Patients with high income can be provided with high-quality services which can be used to generate income to subsidize services for patients with low income, who could otherwise not afford treatment. This model has been successful in India, but needs to be developed and implemented in other regions.

Fees from patients with less severe eye problems can be a source of income to subsidize services for low-income patients who are blind, or in danger of going blind. For example, income from reading spectacles can be used to subsidize cataract surgical costs.

(b) **Government subsidy**

Governments in developing countries have very limited and often decreasing resources for health care, and prevention of blindness is usually not seen as a priority, despite the evidence that restoration or preservation of sight is an extremely cost-effective health intervention. Greater awareness needs to be created within governments of the benefits of preventing and curing blindness,
although it can generally not be expected that governments will increase their resource allocations to blindness prevention; in most developing countries, there will be attempts to develop a mix of governmental and nongovernmental financing of health care, and this could form a good basis also for blindness prevention work.

(c) Insurance schemes

Private or governmental health insurance schemes are available in a number of countries to assist patients in covering the cost of medical treatment. These schemes, however, are most often found in the developed nations, and so far there is usually limited coverage of poor population groups in the developing countries; in fact, in many instances such insurance schemes cover only government employees and people with remunerated posts.

(d) Voluntary and private sector

There is a group of nongovernmental development organizations (NGDOs) which are particularly active in the field of blindness prevention. Increasing competitiveness in the donor market has meant that most organizations struggle to maintain a stable level of income for support of eye care activities in the developing world. For this group of NGDOs, the development of a global plan is seen as an important instrument to create awareness and encourage new sources of revenue from private donors which would become available for blindness prevention.

(e) Bilateral and multilateral governmental agencies

Recent reports and initiatives have clearly documented that health care and, particularly, blindness prevention can have important developmental and economic benefits for people, particularly in developing countries. It is envisaged that a coordinated global initiative to eliminate avoidable blindness would be of interest to donor agencies in the developed countries, as part of aid for poverty alleviation and community development.

1.6 INTERACTION AND COORDINATION BETWEEN INTERESTED PARTIES

As previously discussed in sections 1.4.2 and 1.4.4, various bodies and mechanisms are already in place for interaction on the global plan. In particular, the WHO/PBD Programme will play the lead role, in close consultation with the Task Force of NGDOs; and the regional workshops of IAPB offer an appropriate forum for all interested parties to interact in addressing regional priorities and initiatives. The importance of bringing new actors on the scene - in particular the World Bank and UNICEF, already directly involved in blindness prevention activities - was underlined. Furthermore, the link to governmental development agencies needs to be strengthened.

The role of governments, through their ministries of health, is crucial for the success of any long-term plan for global blindness prevention. The development of appropriate and effective national programmes for the prevention of blindness will be the key to large-scale, coordinated action, with input from collaborating nongovernmental organizations at the international, regional and country level, as well as the private sector. There is a strong rationale for national plans and programmes for blindness prevention in all countries, even if needs and opportunities for intervention vary between countries. It is essential that ministries of health maintain, through an appropriate national committee or similar body, the setting of technical standards and norms and that they issue needed guidelines, coordinate the input from all parties, and arrange for regular monitoring and evaluation of activities and achievements. As a rule, programme evaluations should include external, neutral parties, and the WHO Programme should be available, in consultation with interested collaborating centres or others, to undertake such evaluations at the invitation of national authorities.
Considering the present and future global situation as far as blindness and visual disability are concerned, there is a very strong rationale for increased preventive measures, in order:

- to remove socioeconomic barriers to community developments in developing countries;
- to reduce costs for medical and social care for the visually disabled;
- to provide optimal opportunities for individual achievements and quality of life for all;
- to apply cost-effective interventions against avoidable blindness;
- to achieve feasible global action to control blindness and visual disability as a public health problem.
Section 2

Outline of main activities within a
Global Initiative for the Elimination of Avoidable Blindness

INTRODUCTION

There are three essential elements to a global plan for the elimination of avoidable blindness:

(a) Strategies/targets for disease control
(b) Human resource needs and development
(c) Infrastructure/technology needs and development

2.1 CONTROL OF MAJOR CAUSES OF BLINDNESS

Disease: Cataract

Aim: Elimination of cataract blindness (person with less than 3/60 in both eyes)

Present situation:

1. Cataract (opacification of the lens) is the major cause of blindness in the world (an estimated 16-20 million people bilaterally blind from cataract) and the number is increasing. This is the prevalence (backlog) of cataract blind.

2. It is estimated that in Africa and Asia at least one person per 1000 population goes blind from cataract every year, i.e., 600 000 per year in Africa and 900 000 per year in India. This is the incidence of cataract blindness.

3. Cataract is more common with increasing age. Other less common causes of cataract are injury, other eye diseases (uveitis) and diabetes, and it sometimes occurs in children.

4. There is no known prevention of cataract due to ageing. Treatment involves removal of the lens and then correction of the optical error known as aphakia.

There are two ways in which the cataract can be removed:

(a) Intracapsular cataract extraction (ICCE) - remove the whole lens intact.
(b) Extracapsular cataract extraction (ECCE) - open the lens capsule, remove the lens cortex and nucleus, but leave the capsule in place.
There are three ways of correcting aphakia:

(a) Spectacles

(b) Contact lens

(c) Intraocular lens

5. The cataract surgical rate is a quantifiable measure of the delivery of cataract services. It is the number of cataract operations/million population/per year. In Europe this is about 3000, in India 2000, in Latin America 500-1500, and in Africa generally less than 500.

The cataract surgical rate is meaningful to estimate only when there is ample information on all cataract surgery performed in a country, for example including the private sector.

Objectives: To provide cataract surgical services which:

(a) have a high success rate in terms of visual outcome and improved quality of life;

(b) are affordable for all people (fees from services to high-income patients may be used to subsidize services for low-income patients);

(c) are accessible to rural as well urban populations;

(d) cater for the number of new cases/year (incidence) and so eliminate the backlog of cataract over a number of years.

Indicators:

1. Global and national prevalence of cataract blindness

2. Regional and national cataract surgical rates

3. Proportion of aphakia/pseudophakia in relation to cataract blind, in defined population groups

Strategies:

1. Create demand for service by overcoming barriers to uptake of services, through a variety of community interactions. The major barriers to uptake of cataract services are:
   - lack of awareness;
   - poor quality of service;
   - high cost of treatment;
   - accessibility not easy.

2. Develop and mobilize national (and expatriate) manpower and resources to provide cataract services. The training and use of ophthalmic assistants can allow
ophthalmologists more time for eye surgery. Private ophthalmologists should be encouraged to be actively involved in outreach programmes where this is appropriate.

3. Promote cataract surgical services at a cost which all patients can afford, so that cost is not an obstacle to obtaining the operation. This may involve different tiers of payment, and subsidy for poor patients.

4. Promote cataract surgical services which are available close to where people live, so that distance is not an obstacle to obtaining the operation. Outreach into remote areas should be carried out where appropriate.

5. Enlist the help of community health and community-based rehabilitation workers to identify people with cataract and to provide follow-up and rehabilitation for patients after cataract operation.

6. In the provision of surgery, priority should be given to bilaterally blind patients with cataract. However, patients should be encouraged to seek treatment before becoming blind, thereby preventing blindness from cataract and reducing patient dependence on the family and society. When unilateral cataract is operated on, particular efforts should be made to provide for intraocular lens implantation.

7. Ensure coordination between governmental and nongovernmental service delivery.

8. Develop methods and data for assessment of cataract incidence.


Targets:

1. Global cataract prevalence targets 1990-2020

<table>
<thead>
<tr>
<th>Year</th>
<th>Population (millions)</th>
<th>Projected no. cataract blind at 1995 service level (millions)</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>No. cataract blind (millions)</td>
</tr>
<tr>
<td>1990</td>
<td>5400</td>
<td>16.0</td>
<td>16.0</td>
</tr>
<tr>
<td>1995</td>
<td>5700</td>
<td>20.0</td>
<td>20.0</td>
</tr>
<tr>
<td>2000</td>
<td>6100</td>
<td>25.0</td>
<td>15.0</td>
</tr>
<tr>
<td>2010</td>
<td>6800</td>
<td>35.0</td>
<td>7.0</td>
</tr>
<tr>
<td>2020</td>
<td>7800</td>
<td>50.0</td>
<td>0</td>
</tr>
</tbody>
</table>
2. Global cataract surgical rate targets 1995-2020

<table>
<thead>
<tr>
<th>Year</th>
<th>Global cataract surgical rate (cataract operations/million population/year)</th>
<th>Global no. of cataract operations (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>1100</td>
<td>7.0</td>
</tr>
<tr>
<td>2000</td>
<td>2000</td>
<td>12.0</td>
</tr>
<tr>
<td>2010</td>
<td>3000</td>
<td>20.0</td>
</tr>
<tr>
<td>2020</td>
<td>4000</td>
<td>32.0</td>
</tr>
</tbody>
</table>
3. Regional cataract surgical rate targets 1995-2000

<table>
<thead>
<tr>
<th>Region</th>
<th>Year 1995</th>
<th></th>
<th></th>
<th>Year 2000</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Population (millions)</td>
<td>No. of cataract operations (millions)</td>
<td>Cataract surgical rate (cat. ops/million/year)</td>
<td>Population (millions)</td>
<td>Target cataract operations (millions)</td>
<td>Target cataract surgical rate (cat. ops/million/year)</td>
</tr>
<tr>
<td>India</td>
<td>950</td>
<td>1.6</td>
<td>1800</td>
<td>1000</td>
<td>3.0</td>
<td>3000</td>
</tr>
<tr>
<td>China</td>
<td>1250</td>
<td>0.2</td>
<td>200</td>
<td>1300</td>
<td>1.4</td>
<td>1100</td>
</tr>
<tr>
<td>Rest-of-Asia and Middle-Eastern Crescent</td>
<td>1300</td>
<td>0.8-1.3</td>
<td>600-1000</td>
<td>1450</td>
<td>2.2</td>
<td>1500</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>550</td>
<td>0.1-0.2</td>
<td>200-400</td>
<td>600</td>
<td>0.6</td>
<td>1000</td>
</tr>
<tr>
<td>Latin America and Caribbean</td>
<td>500</td>
<td>0.8-0.5</td>
<td>600-1000</td>
<td>550</td>
<td>1.1</td>
<td>2000</td>
</tr>
<tr>
<td>Former socialist economies of Europe</td>
<td>350</td>
<td>0.3-0.5</td>
<td>1000-1500</td>
<td>375</td>
<td>0.7</td>
<td>2000</td>
</tr>
<tr>
<td>Established market economies</td>
<td>800</td>
<td>2.5-3.5</td>
<td>3100-4400</td>
<td>825</td>
<td>3.0</td>
<td>3500</td>
</tr>
<tr>
<td>Total</td>
<td>5700</td>
<td>5.8-7.8</td>
<td>1100</td>
<td>6100</td>
<td>12.0</td>
<td>2000</td>
</tr>
</tbody>
</table>
4. Costing of subsidy for cataract surgery based on the target for year 2000

<table>
<thead>
<tr>
<th>Region</th>
<th>Population (millions)</th>
<th>Target cataract surgical rate (per million population/year)</th>
<th>Total no. of cataract ops (millions)</th>
<th>Subsidy %</th>
<th>No. operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>1000</td>
<td>3000</td>
<td>3.0</td>
<td>20</td>
<td>600 000</td>
</tr>
<tr>
<td>China</td>
<td>1300</td>
<td>1100</td>
<td>1.4</td>
<td>20</td>
<td>280 000</td>
</tr>
<tr>
<td>Rest of Asia and Middle-Eastern Crescent</td>
<td>1450</td>
<td>1500</td>
<td>2.2</td>
<td>20</td>
<td>440 000</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>600</td>
<td>1000</td>
<td>0.6</td>
<td>80</td>
<td>480 000</td>
</tr>
<tr>
<td>Latin America and Caribbean</td>
<td>550</td>
<td>2000</td>
<td>1.1</td>
<td>10</td>
<td>110 000</td>
</tr>
<tr>
<td>Former socialist economies of Europe</td>
<td>375</td>
<td>2000</td>
<td>0.7</td>
<td>10</td>
<td>70 000</td>
</tr>
<tr>
<td>Established market economies</td>
<td>825</td>
<td>3500</td>
<td>3.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>6100</td>
<td>2000</td>
<td>12.0</td>
<td></td>
<td>1 980 000</td>
</tr>
</tbody>
</table>

1 980 000 cataract operations at a subsidy of US$ 40 per operation = US$ 79.2 million.
Disease: TRACHOMA

Aim: Elimination of blindness due to trachoma

Present situation:

1. An estimated 146 million people have the active infection with the microorganism *Chlamydia trachomatis*, for which antibiotic treatment is indicated.

2. There are approximately 10.6 million adults with inturned eyelashes (trichiasis/entropion), for which eyelid surgery is needed to prevent blindness.

3. An estimated 5.9 million adults are blind from corneal scarring due to trachoma.

4. Trachoma is common in areas of the world characterized by:
   (a) lack of water;
   (b) lack of sanitation;
   (c) excess of flies;
   (d) lack of health/eye care services;
   (e) poverty and isolation.

Indicators:

1. Trichiasis in adults

2. Active infection in children

3. Implementation of the SAFE strategy in countries with blinding trachoma

Strategies: Implementation of the SAFE strategy integrated within primary health care in all communities identified as having blinding trachoma within a country. This includes the following:

1. Assessment to identify communities with blinding trachoma.

2. Delivery of community-based trichiasis Surgery by trained paramedical staff (S of SAFE).

3. Antibiotic treatment (either tetracycline ointment or azithromycin suspension) for children with active disease (A of SAFE).

4. Promotion of Facial cleanliness (F of SAFE) and Environmental improvement (E of SAFE), including personal hygiene and community sanitation as part of primary health care.
Targets:

1. Global trachoma targets for cases of trichiasis and active infection, 1995-2020

<table>
<thead>
<tr>
<th>Year</th>
<th>Total population (millions)</th>
<th>No. with trichiasis (TT) (millions)</th>
<th>No. with active disease (TF) (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>5700</td>
<td>10.0</td>
<td>146.0</td>
</tr>
<tr>
<td>2000</td>
<td>6100</td>
<td>10.0</td>
<td>120.0</td>
</tr>
<tr>
<td>2010</td>
<td>6800</td>
<td>5.0</td>
<td>60.0</td>
</tr>
<tr>
<td>2020</td>
<td>7800</td>
<td>0</td>
<td>8.0*</td>
</tr>
</tbody>
</table>

* This is equivalent to a prevalence of TF of 5% in the at-risk population of 800 million, of whom 160 million would be children aged 0-10 years.

2. Cumulative numbers of countries for implementation of the SAFE strategy in 49 countries* with blinding trachoma, 1995-2020

<table>
<thead>
<tr>
<th>Year</th>
<th>Eastern Mediterranean</th>
<th>Africa</th>
<th>South-East Asia and Western Pacific</th>
<th>Americas</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2000</td>
<td>5</td>
<td>10</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>2010</td>
<td>7</td>
<td>20</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>2020</td>
<td>10</td>
<td>30</td>
<td>7</td>
<td>2</td>
</tr>
</tbody>
</table>

* See WHO report on “Planning for the Global Elimination of Trachoma (GET)” - document WHO/PBL/97.60.
Disease: **Onchocerciasis**

**Aim:** Elimination of blindness due to onchocerciasis

**Present situation:**
1. An estimated 17 million people are infected with onchocerciasis.
2. Approximately 0.3-0.6 million are blind from the disease.
3. The disease is endemic in 30 countries of Africa and occurs in a few foci in six Latin American countries and in Yemen.

**Indicators:**
1. National onchocerciasis control programmes with satisfactory coverage
2. Zero incidence of blindness from onchocerciasis

**Strategies:**
1. Establish sustainable community-based ivermectin distribution programmes in areas of hyper- and mesoendemic disease.
2. Implement local vector control in selected foci where appropriate.
3. Establish surveillance mechanisms for recrudescence of disease and for new cases of blindness.
4. Implement the control programmes through the Onchocerciasis Control Programme (OCP, 11 countries of West Africa), the African Programme for Onchocerciasis Control (APOC, 19 countries of Africa) and the Onchocerciasis Elimination Programme in the Americas (OEPA, 6 countries of Latin America).

**Targets:**

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>National onchocerciasis control programme with satisfactory coverage in onchocerciasis-blinding areas</td>
<td>25 countries</td>
<td>37 countries</td>
<td>37 countries</td>
</tr>
<tr>
<td>Incidence of blindness from onchocerciasis</td>
<td>Surveillance systems being established</td>
<td>Surveillance systems in place</td>
<td>No new cases in all countries</td>
</tr>
</tbody>
</table>
Cause: CHILDHOOD BLINDNESS

Aim: To eliminate avoidable causes of childhood blindness

Present situation:

1. There are an estimated 1.5 million blind children in the world, of whom 1 million live in Asia and 300 000 in Africa. The prevalence is 0.5-1 per 1000 children aged 0-15 years.

2. There are an estimated 500 000 children going blind each year (one per minute). Many of these children die in childhood.

3. The causes of childhood blindness vary from place to place and change over time. The major causes are as follows:

- **Africa**
  - Corneal ulcer/scar (measles, vitamin A deficiency and harmful traditional practices)
  - Congenital cataract
  - Hereditary disorders

- **Asia**
  - Vitamin A deficiency
  - Congenital cataract/rubella
  - Hereditary retinal diseases

- **Latin America**
  - Congenital cataract and glaucoma/rubella
  - Retinopathy of prematurity

- **Industrialized countries and urban centres**
  - Retinopathy of prematurity
  - Congenital cataract
  - Hereditary diseases

4. It is estimated that childhood blindness causes 75 million blind years (number blind x length of life), second only to cataract.

Objectives:

1. To develop promotive and preventive eye disease programmes to stop childhood eye disease and visual loss from:

   - vitamin A deficiency
   - measles
   - harmful traditional practices
   - ophthalmia neonatorum
   - eye injuries

2. To develop therapeutic and surgical services to treat children with:

   - cataract
   - glaucoma
   - corneal ulcer/scar
   - retinopathy of prematurity
3. To develop optical and low vision services for children with refractive errors or low vision, but with useful potential vision.

**Strategies:**

1. To identify areas where childhood blindness from preventable disease is common and to encourage preventive measures, for example:

   (a) measles immunization;
   (b) vitamin A supplementation;
   (c) nutrition education;
   (d) avoidance of harmful traditional practices;
   (e) monitoring of use of oxygen in newborns.

2. To provide specialist training and services for the management of surgically remediable visual loss in children from:

   (a) congenital cataract;
   (b) congenital glaucoma;
   (c) corneal scar;
   (d) retinopathy of prematurity.

3. To develop low vision services for visually handicapped children.

4. To promote school screening programmes for the diagnosis and management of common conditions, i.e.:

   (a) refractive errors, particularly myopia;
   (b) trachoma (in endemic areas).

5. To promote education about “How to look after your eyes” as part of the normal school curriculum for children.

6. To make sure that all children in blind schools are examined by an ophthalmologist (using the WHO form where possible) and receive medical, surgical, optical or low vision service to maximize potential vision.

**Targets:** See “"Vitamin A deficiency" and "Surgically avoidable causes" for details.

**VITAMIN A DEFICIENCY**

**Aim:** To achieve and sustain the elimination of blindness due to vitamin A deficiency.

**Indicators:**

1. Surveillance systems for blinding xerophthalmia

2. Incidence of blinding xerophthalmia
Strategies: The control of xerophthalmia is expected to be achieved by the year 2000 through the Global Child Survival Programme. This consists of a number of short-, medium- and long-term strategies.

1. To work closely with nutrition, immunization and PHC systems to achieve and sustain elimination of vitamin A deficiency.

2. To establish surveillance systems to identify any new cases of blinding xerophthalmia and report the occurrence for action by child survival programmes.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>1995</th>
<th>2000</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surveillance system</td>
<td>Being established</td>
<td>In place in all countries</td>
<td>Maintenance as needed in selected countries</td>
</tr>
<tr>
<td>Incidence of blindness</td>
<td>?</td>
<td>Nil in all countries</td>
<td>Nil in all countries except disaster situations</td>
</tr>
</tbody>
</table>

**SURGICALLY AVOIDABLE CAUSES**

Aim: To control blindness in children from cataract, glaucoma and retinopathy of prematurity (ROP).

Indicators:

1. Number of eye centres with paediatric-oriented services

2. Number of surgical procedures for childhood cataract, glaucoma and retinopathy of prematurity

Strategies:

1. Strengthen or develop the expertise and capabilities within existing eye units to provide surgical services for children with avoidable blindness, including follow-up and low vision services. Such centres could be established on a national, regional or subregional level.

2. Encourage early diagnosis and referral of children needing eye surgical services.

3. Increase screening practices for ROP in neonatal units.

4. Monitor the changing patterns in blinding eye disease in children, so that the appropriate control measures can be implemented.
Targets:

<table>
<thead>
<tr>
<th>Year</th>
<th>Population aged 0-15 years (millions)</th>
<th>Number of blind children</th>
<th>Target (millions/prevalence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>1800</td>
<td>1.45</td>
<td>1.45 (0.8/1000)</td>
</tr>
<tr>
<td>2000</td>
<td>2000</td>
<td>1.60</td>
<td>1.40 (0.7/1000)</td>
</tr>
<tr>
<td>2010</td>
<td>2200</td>
<td>1.80</td>
<td>1.20 (0.5/1000)</td>
</tr>
<tr>
<td>2020</td>
<td>2500</td>
<td>2.00</td>
<td>1.0 (0.4/1000)</td>
</tr>
</tbody>
</table>

Cause: **REFRACTIVE ERRORS AND LOW VISION**

**Aim:** Elimination of visual impairment (less than 6/18) and blindness due to refractive errors or other causes of low vision. This aim goes beyond the elimination of blindness and also includes the provision of services for individuals with low vision.

**Present situation:**

1. Spectacles are an essential part of the treatment of many eye patients. Their provision is therefore an integral part of eye care delivery.

2. The steps in the provision of refraction services and low vision care for a patient are as follows:
   - **Screening:** Identification of individuals with poor vision which can be improved by spectacles or other optical devices.
   - **Refraction:** Evaluation of the patient to determine what spectacles or device may be required.
   - **Manufacture:** Manufacture of the spectacles or an appropriate device, both of which may be manufactured locally, purchased externally, or donated.
   - **Dispensing:** Issuing of the spectacles or device, ensuring a good fit of the correct prescription.
   - **Follow-Up:** Repair of spectacles/devices or repeat dispensing.

**Indicator:** Prevalence of blindness and visual impairment due to uncorrected refractive errors or other causes of low vision
Strategies:

1. Create awareness and demand for refractive services through community-based services/primary eye care and school screening.

2. Develop accessible refractive services for individuals identified with significant refractive errors. This will require training in refraction and dispensing for paramedical eye workers if ophthalmologists and/or refractionists are not available in sufficient number.

3. Ensure that optical services provide affordable spectacles for individuals with significant refractive errors.

4. Develop and make available low vision services and optical devices for all those in need, including children in blind-school or integrated education. Certain low vision devices can be manufactured locally, or purchased externally in bulk supplies to reduce costs.

5. Include the provision of comprehensive low vision care as an integral part of national programmes for the prevention of blindness, or rehabilitative services for the visually disabled.
2.2 HUMAN RESOURCE DEVELOPMENT

2.2.1 COMMUNITY LEVEL

**Background:** Primary health care (PHC) is a fundamental concept of the World Health Organization for improvement in health. The main activities in PHC are:

(a) immunization;
(b) better nutrition;
(c) water and sanitation programmes;
(d) control of common diseases (endemic and epidemic);
(e) delivery of maternal and child health care;
(f) health education;
(g) simple treatment;
(h) essential drugs supply.

Prevention of blindness activities lend themselves admirably to integration within primary health care, and the eight essential elements all have a relevance in varying degrees to the prevention and control of the major blinding diseases.

**Aim:** The PHC approach to prevention of blindness. The provision of eye care as an integral part of primary health care is a key strategy that is adopted in all national programmes.

**Strategies:** To use PHC activities to prevent diseases that may lead to blindness and visual impairment (primary and secondary prevention) and to facilitate referral for sight-restoration surgery for cataract (tertiary prevention) through patient education and motivation. Where community-based rehabilitation (CBR) projects are ongoing, CBR workers may help in identifying blind and visually impaired persons for referral.

**Elements of PHC**

The following exemplify the manner in which the elements of primary health care contribute to prevention of blindness:

- **Immunization:** The expanded programme on immunization (EPI) can result in prevention of blindness from measles. Immunization programmes can include the distribution of vitamin A supplements. Rubella immunization programmes prevent congenital rubella syndrome including blindness.

- **Nutrition:** Better nutrition, particularly with vitamin A, can prevent xerophthalmia and the resultant blindness.

- **Water and sanitation:** Both water and sanitation have a direct relevance to the prevention of blindness from trachoma, where personal hygiene (clean face) and environmental hygiene are critical parts of the SAFE strategy.

- **Control of common diseases:** Treatment of trachoma or onchocerciasis in endemic areas can reduce the prevalence of visual loss from these eye diseases.

- **Maternal/child health care:** Better care of the pregnant woman and young child can lead to less visual disability as a result of pregnancy and childbirth.
- **Health education:** Many causes of blindness can be prevented by health education, for example trauma.

- **Essential drugs supply:** It is important that tetracycline eye ointment be available for treatment of trachoma and other common eye infections, vitamin A capsules for treatment of xerophthalmia, and ivermectin for treatment of onchocerciasis.

- **Primary eye care (PEC) as part of PHC:** Primary eye care as an integral part of primary health care is a key strategy that is adopted in all national programmes. It includes promotion of eye health and the provision of basic preventive and/or curative treatment for common eye disorders.

The role of the PHC worker

- **Identification:** PHC workers are ideally placed to identify blind and visually disabled children and adults in their own homes.

- **Assessment and diagnosis:** PHC workers can be taught to assess those individuals who could be helped by the services of a specialist, for example identifying cataract for referral to an ophthalmologist.

- **Referral for management and treatment:** PHC workers can encourage individuals to go for treatment and can provide the referral system that will promote this.

- **Follow-up and evaluation:** After treatment, the PHC worker can follow up the patient at home to help with visual rehabilitation (the patient after cataract surgery, for example), give advice on any treatment and make sure that spectacles are available.

---

**Eye care personnel**

The categories of health personnel involved in the provision of eye care at different levels vary from country to country. In the present document, reference is made to some only of these categories, considering common staff at the specialist care level, auxiliary clinical personnel, and staff developments for management and technology. In addition, there are other professional categories in many countries, for example optometrists, orthoptists, ophthalmic and dispensing opticians, and others involved in certain elements of eye care, in particular refraction and low vision services.
2.2.2 SECONDARY AND TERTIARY LEVELS

Africa is considered the region of the world with the greatest need for human resource development for eye care. The targets given are therefore minimum figures for Africa. Higher targets can be anticipated for other regions of the world.

Category of health personnel: Ophthalmologists

Objective: To retain and utilize ophthalmologists in an effective and efficient eye care service and to achieve a ratio of at least one ophthalmologist per 250,000 population.

Indicator: Number of ophthalmologists/population

Strategies:

1. Create one ophthalmologist post and facility per 250,000 population through government and/or private sector with equal distribution for urban and rural populations.

2. Increase quality and productivity of existing training centres for ophthalmologists.

3. Increase number of training centres for ophthalmologists, where appropriate.

4. Attract and retain staff through appropriate incentives including career structure and remuneration.

5. There should be an evaluation of the two-year diploma courses (for example Bangladesh and West Africa), and similar courses should be developed if the results are positive.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmologists per population:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>1:500,000</td>
<td>1:400,000</td>
<td>1:250,000</td>
</tr>
<tr>
<td>Asia</td>
<td>1:200,000</td>
<td>1:100,000</td>
<td>1:50,000</td>
</tr>
</tbody>
</table>

Category of health personnel: Ophthalmic medical assistants and ophthalmic nurses

Objective: Where there are insufficient ophthalmologists, train OMAs and ophthalmic nurses for secondary eye care, so that there is a minimum of one OMA or eye nurse per 200,000 population, improving to one per 100,000 over time.

Indicator: Proportion of OMAs/eye nurses per population
Strategies:

1. Establish OMA/ophthalmic nurse training in eye care, based on country needs.
2. Establish OMA/ophthalmic nurse training in cataract surgery, based on country needs.
3. Secure funded posts for trainees.
4. Integrate OMA/ophthalmic nurse services in health care systems.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMAs or eye nurses per population:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>1 : 400 000</td>
<td>1 : 200 000</td>
<td>1 : 100 000</td>
</tr>
<tr>
<td>Asia</td>
<td>1 : 200 000</td>
<td>1 : 100 000</td>
<td>1 : 50 000</td>
</tr>
</tbody>
</table>

Category of health personnel: Other medical staff

Objectives:

1. All medical graduates to be trained in basic eye care.
2. Where needed, training of other medical staff, for example doctors and surgeons in eye care, including cataract surgery where appropriate.

Indicator: Proportion of medical graduates with basic eye care training

Strategies: International Council of Ophthalmology and ophthalmological societies to work towards including core ophthalmology content in medical curriculum and postgraduate medical education, using appropriate available models.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of medical schools teaching basic eye care</td>
<td>50%</td>
<td>90%</td>
<td>100%</td>
</tr>
</tbody>
</table>
Category of health personnel: Refractionists

Objective: To train sufficient and appropriate staff for refraction of underserved populations.

Indicator: Proportion of refractionists per population

Strategies: Develop training programmes in refraction for appropriate staff, based on the country needs and resources.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of trained refractionists per population</td>
<td>1:250 000</td>
<td>1:100 000</td>
<td>1:50 000</td>
</tr>
</tbody>
</table>

Category of health personnel: Managers

Objectives:

1. To provide training in basic principles of management for medical/paramedical staff.

2. To provide trained managers for tertiary and large secondary eye care facilities and programmes.

Indicator: Trained managers at facilities and in programmes

Strategies:

1. Short courses in planning and management for eye care at regional or country level.

2. Development of courses in eye care programme management at selected venues for full-time managers.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of tertiary facilities with trained managers</td>
<td>20</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>% of secondary facilities with trained managers</td>
<td>5</td>
<td>25</td>
<td>50</td>
</tr>
</tbody>
</table>
Category of health personnel: Equipment technicians

Objective: To develop manpower for equipment maintenance/repair, low-cost spectacle production and eye drop preparation.

Indicators:
1. Proportion of tertiary eye facilities with trained technicians
2. Proportion of secondary eye facilities with trained technicians

Strategies: Short courses on equipment maintenance, at the regional or country level.

Targets:

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of tertiary eye facilities with a trained technician</td>
<td>20%</td>
<td>60%</td>
<td>100%</td>
</tr>
<tr>
<td>Proportion of secondary eye facilities with a trained technician</td>
<td>5%</td>
<td>25%</td>
<td>50%</td>
</tr>
</tbody>
</table>
2.3 INFRASTRUCTURE AND APPROPRIATE TECHNOLOGY DEVELOPMENT

2.3.1 INFRASTRUCTURE

Objective: To provide universal coverage and access to services for the preservation of vision and restoration of sight.

Strategies: Development of district-level eye care services, with primary eye care integrated into the PHC system for a population of between 0.5 and 2 million people.

1. Assessment to determine current infrastructure, capacity and level of utilization.
2. Reorientation to a consumer-provider model within the PHC system.
3. Establishment of productivity norms for key resources (for example cataract surgeries per ophthalmologist per year).
4. Obtaining long-term sustainability through the introduction of user fees where possible.
5. Operations research to determine how to increase the productivity of the available infrastructure.

Generic model

CONSUMER

Patient motivation ↔ to overcome the barriers of:
  lack of awareness, cost, fear, availability

Product acceptance ↔ by ensuring that eye care is:
  good quality, an acceptable cost, easily accessible

PROVIDER

Motivating the consumer

Service delivery ↔ Capacity development
  infrastructure and management system

Motivating providers ↔ Personnel development
  requiring: security, remuneration, work satisfaction and status
<table>
<thead>
<tr>
<th>Level</th>
<th>Activity</th>
<th>Key manpower</th>
<th>Other infrastructure</th>
</tr>
</thead>
<tbody>
<tr>
<td>District</td>
<td>Cataract surgery</td>
<td>Ophthalmologist (1:250 000)</td>
<td>1 eye bed/20 000 population</td>
</tr>
<tr>
<td></td>
<td>Refraction services</td>
<td>Ophthalmic assistant/nurse (1:100 000)</td>
<td>1 eye operating theatre per district</td>
</tr>
<tr>
<td></td>
<td>Spectacle supply</td>
<td>Manager (1 or 2 per district)</td>
<td>1 spectacle workshop and eye drop unit per district (optional)</td>
</tr>
<tr>
<td></td>
<td>Training</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Outreach activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coordination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subdistrict</td>
<td>Case referral</td>
<td>As above</td>
<td>Refraction facility</td>
</tr>
<tr>
<td></td>
<td>Outreach cataract surgery</td>
<td></td>
<td>Spectacle dispensary</td>
</tr>
<tr>
<td></td>
<td>Refraction services</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trichiasis surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>Screening/case referral</td>
<td>PHC worker trained in primary eye care</td>
<td>Vision measurement</td>
</tr>
<tr>
<td></td>
<td>Health education</td>
<td>(1:5000)</td>
<td>Basic eye medicines:</td>
</tr>
<tr>
<td></td>
<td>Treatment of common eye infections</td>
<td></td>
<td>tetracycline eye ointment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>vitamin A capsules</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(ivermectin)</td>
</tr>
</tbody>
</table>

**Indicators:**

1. Ratio of ophthalmologists, ophthalmic assistants and other personnel to population
2. Proportion of district eye units with personnel and facilities
3. Proportion of PHC workers trained in primary eye care
4. Cataract surgical rate (cataract operations/million population/year)
5. Spectacles dispensed per million population

**Targets:** For infrastructure development, access, utilization and coverage

<table>
<thead>
<tr>
<th>Target</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of</td>
<td>50%</td>
<td>90%</td>
<td>95%+</td>
</tr>
<tr>
<td>infrastructure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accessibility</td>
<td>40%</td>
<td>75%</td>
<td>90%+</td>
</tr>
<tr>
<td>Utilization</td>
<td>25%</td>
<td>50%</td>
<td>90%+</td>
</tr>
<tr>
<td>Coverage</td>
<td>25%</td>
<td>50%</td>
<td>90%+</td>
</tr>
</tbody>
</table>
2.3.2 TECHNOLOGY

Background:

1. There exist, in many parts of the world, shortages of usable diagnostic and therapeutic equipment necessary for practitioners to apply modern, but fundamental, techniques in their efforts to combat blindness.

2. Countries requiring appropriate technology often do not have access to the information necessary to acquire such equipment and instruments. Because information on low-cost technologies does not reach the decision-makers, inappropriate or extravagant purchases are often made, leaving the users with sophisticated equipment which is too expensive to operate, maintain and repair.

3. Local doctors do not know how to maintain and repair their equipment. Local biomedical engineers and technicians do not receive training in the basic and complex repairs of ophthalmic instrumentation. Commercial service providers, either direct manufacturers' representatives or independent service organizations (ISOs), are too distant or too costly for local practitioners, clinics or hospitals to afford. Where sophisticated technology has been introduced, the equipment is often broken, unserviceable, or inappropriate.

Objectives:

1. To provide practitioners, hospitals and clinics with information on good-quality and affordable appropriate technology.

2. To ensure availability of spectacles, ophthalmic supplies and equipment at costs appropriate to local economies, as and when required.

3. To provide appropriate donated equipment to countries which cannot afford its purchase.

4. To assist users to evaluate, select and purchase appropriate equipment using methods which will help to prolong its useful life.

5. To provide training, using seminars and teaching materials, to doctors and technical support staff so that they are capable of maintaining and repairing their own ophthalmic equipment.

6. To introduce new technologies such as computers and computer networks to improve management efficiency and information exchange.
Strategies:

1. Encourage the development of a worldwide communications network for providing information on ophthalmic equipment and appropriate technology.

2. Conduct feasibility studies on new technologies to ensure cost-effectiveness.

3. Distribute information from international nongovernmental development organizations (INGDOs) of recommended equipment and instruments to practitioners and purchasing authorities.

4. Establish a purchasing consortium to procure and distribute supplies and equipment to obtain best prices.

5. Establish regional training centres with faculty and equipment capable of providing short courses for technicians and engineers (and practitioners, if appropriate).

6. Encourage local entrepreneurs to produce basic supplies (eye drops, spectacles, etc.).

7. Facilitate technology transfer (for example augment the existing technical library of video and written materials which can be donated to eye care institutions and training centres).

Criteria for developing local production:

1. Costs are high and can be reduced by local production.

2. Supplies are not dependable.

3. Supply time is unacceptably long.

Indicator: Proportion of district eye units providing adequate eye medicines, spectacles and other eye services

Targets: See the table for infrastructure development for details.
Section 3

Structure and work plan development for the Global Initiative for the Elimination of Avoidable Blindness

INTRODUCTION

- The Global Initiative will intensify and accelerate present prevention of blindness activities so as to achieve the goal of eliminating avoidable blindness by 2020.

- It will focus initially on certain diseases which are the major causes of blindness and for which proven cost-effective interventions are available.

- It will establish a structure for the focused planning, coordination and implementation of programmes between national governments, NGDOs, the private sector and the donor community.

- It provides a common theme and goal to be used by individual NGDOs in advocacy and fundraising; the common goal with defined targets will allow for resource mobilization from multilateral donors and large foundations which may not be accessible to individual NGDOs alone.

- It will expand the existing technical assistance of the WHO Programme to countries, to facilitate sustainable programme development and service delivery in collaboration with NGDOs and donor agencies.

3.1 STRUCTURE FOR THE GLOBAL INITIATIVE

3.1.1 Coordination

At the GLOBAL level, this would be achieved through existing mechanisms and meetings within the PBD Programme, i.e.:

Programme Advisory Group
International Agency for the Prevention of Blindness (IAPB)
Partnership Committee
Task Force

A post should be developed in PBD for a person to coordinate the Global Initiative.

At the REGIONAL level, the following measures should be taken:

- Appoint a full-time person in WHO/PBD for the African and Eastern Mediterranean Regions (later this may be made two positions).

- Appoint a full-time person in WHO/PBD for the South-East Asia and Western Pacific Regions.
> IAPB Regional Officers to work in close collaboration with the WHO Regional Advisers.

> Regional IAPB workshops to be held every one to two years for exchange of information and reporting from national coordinators.

> Regional versions of the "Global Initiative" document need to be written by 1998. These regional/language-specific versions will be sent to countries as a template for writing/revising national plans.

> Regional programmes should be considered for funding proposals by multilaterals (e.g. regional training programmes in Africa).

At the NATIONAL level:

> Each country to develop or revise its own national plan using the regional document as a template.

> Involvement of the ministry of health and interested NGDOs through national committees or a task force.

### 3.2 PHASES OF IMPLEMENTATION

At the GLOBAL level, consider a three-year planning cycle initially, e.g.:

Phase 1: 1997-1999 to include
- structure development
- advocacy
- planning at regional level
- resource mobilization for 2000-2004

This would be followed by four five-year phases of implementation:

Phase 2: 2000-2004
Phase 3: 2005-2009
Phase 4: 2010-2014
Phase 5: 2015-2019

At the REGIONAL level, Member countries should be assisted by the WHO Advisers in the revision or development of national plans for elimination of avoidable blindness, through site visits and national and intercountry workshops, applying the above phases of implementation.
More specifically, the involvement of countries per region is suggested as follows:

<table>
<thead>
<tr>
<th>Region (Number of countries)</th>
<th>Number of Member countries</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1997-1999</td>
</tr>
<tr>
<td>Africa (46)</td>
<td>23</td>
</tr>
<tr>
<td>Americas (36)</td>
<td>12</td>
</tr>
<tr>
<td>Eastern Mediterranean (22)</td>
<td>7</td>
</tr>
<tr>
<td>Europe (51)</td>
<td>0</td>
</tr>
<tr>
<td>South-East Asia (10)</td>
<td>9</td>
</tr>
<tr>
<td>Western Pacific (28)</td>
<td>15</td>
</tr>
<tr>
<td>Total (193)</td>
<td>66</td>
</tr>
</tbody>
</table>

At the NATIONAL level:

- Each country should constitute a national committee or task force (MOH and NGDO and other interested parties) to execute the national plan.

- Each country should consider development of its own national plan in the following phases:
  - Planning phase
  - Implement strengthened cataract services, in addition to ongoing activities
  - Develop further cataract services and next priority disease
  - Develop further cataract services and all other priority diseases
  - Consolidate services to meet targets

3.3 MONITORING AND EVALUATION

There is need for a management system which is simple and gives useful information to monitor the development and activities of national programmes in terms of process, output and outcome. Existing guidelines from WHO/PBD should be applied and developed further.

Indicators for monitoring the Global Initiative should be developed by the Task Force, taking into account existing criteria for monitoring/evaluation within WHO and IAPB.
### Time-frame for 1997-2000

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Requirements</th>
<th>Action</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1997</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-September</td>
<td>Economics pilot study</td>
<td>US$ 6900</td>
<td>ICEH/Task Force</td>
<td>Ready by 31 August</td>
</tr>
<tr>
<td>9-10 September</td>
<td>Planning meeting with NGDOs</td>
<td></td>
<td>WHO/Task Force</td>
<td></td>
</tr>
<tr>
<td>October-December</td>
<td>Finalization of global document</td>
<td></td>
<td>WHO/IAPB</td>
<td>Send document to all Regions</td>
</tr>
<tr>
<td></td>
<td>Finalize proposal for WHO/HQ post</td>
<td>Funds/person</td>
<td>WHO/Task Force</td>
<td></td>
</tr>
<tr>
<td><strong>1998</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-5 March</td>
<td>China Workshop</td>
<td></td>
<td>WHO/NGDO participants</td>
<td>Develop targets for China plan for cataract</td>
</tr>
<tr>
<td>June (?)</td>
<td>Meeting to develop regional plans</td>
<td>US$ 15 000</td>
<td>WHO/Task Force/IAPB</td>
<td>After launch of the Initiative</td>
</tr>
<tr>
<td>June-September (?)</td>
<td>AMRO Workshop</td>
<td>(US$ 10 000 ?)</td>
<td>WHO (Dr Silva)/Task Force</td>
<td>12 AMRO countries</td>
</tr>
<tr>
<td>Late autumn</td>
<td>AFRO Workshop (Malawi - IAPB)</td>
<td>?</td>
<td>WHO/Task Force/IAPB</td>
<td>Anglophone countries (Dr Chirambo)</td>
</tr>
<tr>
<td>Late autumn</td>
<td>SEARO Workshop (IAPB)</td>
<td>?</td>
<td>IAPB/Task Force</td>
<td>9 countries (Dr Rao)</td>
</tr>
<tr>
<td><strong>1999</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spring</td>
<td>EMRO Workshop/IAPB</td>
<td>?</td>
<td>WHO/Task Force/IAPB</td>
<td>7 countries</td>
</tr>
<tr>
<td>April-June</td>
<td>Regional Advisers’ posts proposal</td>
<td>?</td>
<td>WHO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>finalized</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spring</td>
<td>AFRO Workshop</td>
<td>?</td>
<td>IAPB/WHO/Task Force</td>
<td>Francophone countries</td>
</tr>
<tr>
<td>September</td>
<td>Beijing IAPB Assembly &amp; WPRO Workshop</td>
<td>?</td>
<td>IAPB/WHO/Task Force</td>
<td>15 countries</td>
</tr>
</tbody>
</table>
ANNEX 1

BENEFITS AND COSTS
OF BLINDNESS PREVENTION INITIATIVES

1. INTRODUCTION

Blindness imposes a significant burden on society in terms of human suffering, the cost of lost production and lower productivity and the costs of financing rehabilitation and education of the blind. In addition, some causes of blindness are associated with lower life expectancy in many developing countries. Conversely, prevention and cure of blindness can provide enormous savings in terms of both money and human misery.

In order to obtain an up-to-date assessment of the potential economic benefits of available interventions to prevent and cure blindness, the Task Force of the Partnership Committee commissioned a study to review available literature dealing with the cost-effectiveness and cost-benefit of such interventions. This work was undertaken by Margaret Thomas, a health economist, working under the auspices of the International Centre for Eye Health (1). The comments in this annex are based on this literature search and are confined to selected priority diseases identified in the Global Initiative.

The research identified 274 relevant articles and publications, thus providing a reasonably broad base on which to make assessments. There is a variety of different methodological approaches used in identifying and quantifying the respective costs and benefits associated with PBL interventions, but the most widely used are:

- cost-minimization analyses
- cost-utility analyses
- cost-effectiveness analyses
- cost-benefit analyses

These approaches are discussed fully in the report and are not considered further here. Mention should be made, however, of a particular approach based on cost-utility which has been used increasingly in recent years and recurs frequently in the literature.

The 1993 World Bank World Development Report, “Investing in Health” (2), introduced a measure of health status known as the Disability-Adjusted Life Year (DALY). It is an indicator of the time lived with a disability together with the time lost due to premature mortality. The measure depends on assigning weights to different health states (0 for death through 1.00 for perfect health). These weights are then multiplied by the number of years that the health state exists and discounted at a 3% discount rate to the present. The idea of a single measure of the burden of disease is highly attractive, as it permits comparisons across diseases, populations and countries. When this measure is allied to the availability and costs of interventions, it leads to an assessment of their comparative cost-effectiveness, i.e. cost per DALY saved. This measure is being used frequently in cost-effectiveness studies in the health sector and in many such studies dealing with blindness interventions. A much-quoted list of potential health service interventions grouped by cost per DALY has been produced by Jamison (3) and is referred to later.

DALYs are not without their critics, however. As with all such composite measures of health status, obtaining appropriate weights for mortality and for all possible forms of morbidity is
problematic. The DALY concept is continually being refined to accommodate this and other criticisms but it does serve, meanwhile, to provide a reasonable comparative measure of cost-utility.

The main thrust of the Global Initiative will be in four areas:

- Cataract
- Onchocerciasis
- Trachoma
- Xerophthalmia (vitamin A deficiency)

2. CATARACTS

Cataract is by far and away the major cause of curable blindness worldwide and cataract surgery is a priority area for intervention under the Global Initiative. Vision can be restored by effective surgery involving either intracapsular cataract extraction or extracapsular cataract extraction. There is an increasing body of literature on the costs of different types of cataract interventions, but limited data on cost-effectiveness or economic benefits. However, the evidence which is available demonstrates that cataract surgery is a highly cost-effective health intervention. Below, we look specifically at evidence provided by World Bank research (3) undertaken in the early 1990s and at a more recent study of the Lumbini Zonal Eye Care Programme in Nepal (4).

2.1 Disease control priorities in developing countries

The Health Sector Priorities Review published by the World Bank in 1993 (2) consists of analyses that assess the significance to public health of individual diseases and of what is known about the cost-effectiveness of relevant interventions for their control. The cost-effectiveness of more than 50 specific health interventions was evaluated using a standard methodology for costs and benefits. The cost-effectiveness of interventions was summarized by estimates of marginal cost per DALY gained. Jamison comments:

"... although this measure is imperfect, and often varies with the scale of the control effort and across environments, its estimation, for each of a large number of interventions, does indicate priorities for the allocation of resources to disease control".
The following costs for cataract surgery and costs per DALY saved were given as follows:

### Cost-utility of cataract surgery

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Cost per DALY saved (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.00</td>
<td>15.70</td>
</tr>
<tr>
<td>26.80</td>
<td>21.50</td>
</tr>
<tr>
<td>42.50</td>
<td>31.80</td>
</tr>
<tr>
<td><strong>Bilateral cataract surgery (US$ per eye)</strong></td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td>15.00</td>
</tr>
<tr>
<td>26.80</td>
<td>19.00</td>
</tr>
<tr>
<td>42.50</td>
<td>27.00</td>
</tr>
<tr>
<td><strong>Unilateral cataract surgery (US$ per eye)</strong></td>
<td></td>
</tr>
</tbody>
</table>

Source: Javitt, Chapter 26 - Disease Control Priorities in Developing Countries (Jamison et al., eds, 1993)

This placed cataract surgery as one of the most cost-effective of all public health interventions available and on a par with other well-accepted interventions such as DPT and poliomyelitis immunization (US$ 20-40 per DALY).

### 2.2 Lumbini Eye Care Programme

A comprehensive blindness programme serving two million people living in the Lumbini Zone, south-central Nepal, has been operating since 1985. The programme includes a base eye hospital, field-based services including eye camps, screening camps and district-level clinics. Cataract surgery is performed on an outpatient basis under local anaesthetic followed by seven days of observation at the eye hospital or eye camp. Typically, patients undergo extracapsular cataract removal followed by insertion of a posterior chamber intraocular lens, although a significant percentage of patients undergo intracapsular cataract extraction and receive standard +10 cataract spectacles.

An assessment (4) of the cost-effectiveness of this programme has been undertaken and its findings were as follows: On the basis of an average cost per operation of US$ 21.71, cataract surgery in Lumbini costs US$ 5.06 per DALY. This is even lower than the previously reported World Bank estimates and shows it to be among the few health interventions that cost less than US$ 10 per DALY saved.

Sensitivity analysis was undertaken to test both the upper and the lower limits around these estimates. The following variables were adjusted: case cost, discount rate, rate of surgical success, utility rate for blindness and sight restoration, and mortality rate among unoperated cataract blind. The “worst case” scenario increased the DALY cost to US$ 20.53. This reflected a set of conditions that did not exist in Nepal but which might apply in other countries. But, as noted above, even a DALY cost of this level is highly attractive and suggests that, even under unfavourable conditions, cataract surgery is likely to compare favourably with most other widely accepted public health interventions.
In response to the question of how typical are the conditions in Nepal, the author commented as follows:

“Conditions affecting cost-effectiveness vary from country to country. These include the cost of drugs and supplies, personnel costs, mortality rates and cataract prevalences. Nepal’s poor transportation and communication infrastructure combined with difficult terrain may tend to make programme expenses higher than in many other countries. On the other hand, the low cost of Indian-made supplies and equipment tends to keep costs lower than they might be in other developing country eye care programmes. Purchase costs may also increase in areas with lower cataract prevalences since more resources would need to be devoted to case-finding and to transportation. The prevalence of cataract blindness in Nepal (0.54%) is typical or even somewhat low for a developing country. The rate in Botswana is 0.63%, in Indonesia 0.80% and in Pakistan 1.34%. Overall, this suggests that Nepal is fairly typical of low-income countries as far as the conditions that affect the cost-effectiveness of cataract surgery are concerned.”

2.3 Conclusion

Other studies reported in the literature support the findings of the evidence quoted here. Cataract interventions are highly cost-effective. Although it is a disease of advancing age in the majority of cases, its cost-effectiveness derives from characteristics such as speed of operation (about 30 minutes), the potential for high volume and the fact that cataract surgery is almost always successful. There is clearly scope for more full cost-benefit work (as opposed to just DALY calculations) for different types of cataract interventions, but existing evidence demonstrates the economic efficiency of such interventions. Patients have better vision and improved quality of life, can maintain occupations and activities and can continue life at home.

3. ONCHOCERCIASIS

The fight against onchocerciasis under the initial Onchocerciasis Control Programme (OCP) is now nearing completion. Eleven countries, together with WHO, World Bank and others, have participated in a vector control programme running from 1974 to 2002, with benefits continuing to at least 2012. The programme has been well written up and widely discussed, demonstrating significant benefits - both in health and in economic terms, viz.:

- 34 million people protected
- 600 000 cases of blindness prevented
- 5 million years of productive labour added
- 25 million hectares of arable land freed up
- 12 million children spared the disease

Given the magnitude of the benefits, it is perhaps not surprising that the economic rate of return has been calculated as 20% (5). Unlike the calculation of DALYs saved, this measure values the economic benefits associated with the programme and compares them with total programme costs. With a 20% return, this represents a highly successful intervention, not just in health sector terms but as an investment when compared to other public sector investments.

OCP is being followed by a second programme with the objective of eliminating river blindness as a public health hazard. The African Programme for Onchocerciasis Control (APOC) consists of the same players (although different countries) as OCP but with the addition of NGDOs and Merck & Co. as suppliers of Mectizan® (ivermectin). The coverage of the programme extends beyond the original OCP countries to a further 19 African countries. The benefits which are expected to derive
from this programme are again considerable. Assuming a compliance ratio of 70% (Mectizan® usage among end-users) and a progressive reduction in blindness incidence, reaching 90% in year 6, the following benefits are anticipated:

- 1 million cases of blindness prevented
- 7.8 million years of labour added

This gives an economic rate of return of 18% (6). This is very similar to the cost-benefit return of OCP and likewise represents an excellent return on investment in terms of both health and development.

4. TRACHOMA

There is limited material available on the cost-effectiveness of interventions for the prevention of trachoma. However, a very comprehensive review has been undertaken by economists from the Harvard Center for Population and Development Studies of the trachoma control programme in Myanmar (7).

The paper compares the costs and benefits of two types of trachoma interventions employed over a 30-year period by the trachoma control programme (TCP) in Myanmar. The aim was to derive insights on vertical and horizontal approaches to trachoma control, in addition to identifying the optimal mix of interventions to prevent trachomatous visual impairment. Drawing on studies of the prevalence of trachomatous blindness in Myanmar and of the efficacy of surgical prevention, the effectiveness and utility of non-surgical and surgical interventions were derived. This is expressed as the number of cases of visual impairment prevented and handicap-adjusted life years (HALYs) saved. HALYs, like other composite measures of ill-health such as DALYs (disability-adjusted life years) and QALYs (quality-adjusted life years) expresses as a single unit the years of life lost due to premature mortality and life years lost while living with morbidity, disability or handicap for each individual with a disease.

The total annual average cost-utility of non-surgical interventions (community education and antibiotic treatment) over the 30-year duration of TCP was US$ 11 per HALY saved compared with US$ 59 per HALY saved for surgical intervention. This reduced to US$ 3 and US$ 10 per HALY respectively when comparing marginal cost-utility.

The absence of studies that have used HALYs as a measure of effectiveness limits direct comparison with other studies. However, as noted earlier, Jamison estimates the marginal cost of cataract surgery to be between US$ 18 and US$ 42. The marginal cost per trichiasis surgery performed in Myanmar was between US$ 2 and US$ 15. Assuming the benefits from cataract and trichiasis surgery are similar in that they restore/preserve vision among the elderly, it is reasonable to assume that the cost-effectiveness and utility are similar. Thus both surgical and non-surgical interventions for trachoma control share with cataract surgery the distinction of being among the most cost-effective prevention activities.
5. CHILDHOOD BLINDNESS (XEROPHTHALMIA)

It is estimated that childhood blindness causes 75 million blind years, second only to cataract. Up to half-a-million children go blind annually and up to 80% of those that go blind die within one year (8). Vitamin A deficiency is the major cause. Yet much of this is preventable through the administration of doses of vitamin A. There is a considerable body of literature on the success of vitamin A programmes.

A relatively comprehensive cost-benefit study of a vitamin A intervention for reducing xerophthalmia was undertaken by Popkin et al. (1980) (9). The study was based on data from the Philippines in which the economic benefits of reducing xerophthalmia were viewed as increased income and the reduction in costs of outpatient care because fewer children would die, go blind, or become sick due to the disease. The assumption was that xerophthalmia affects both the future productivity and the development of children aged one through 15. Higher mortality and total blindness from xerophthalmia lower the productive life span. Increased morbidity, mortality and partial blindness reduce future productivity. Reductions in prevalence also reduce treatment costs. Three types of interventions were analysed for their costs and effectiveness in reducing xerophthalmia: mass-dose capsules of vitamin A every six months; fortification of monosodium glutamate (MSG) with vitamin A; and, thirdly, a programme of health and nutrition education, disease prevention through sanitation and immunization, and limited curative work. The benefits were found to be substantially greater than costs for the mass-dose capsule and MSG fortification interventions, but costs exceeded benefits for public health interventions. For the mass-dose capsule, benefits were from 2.4 to 3.4 times the costs. For fortification, the benefits were six to 21 times the costs.

Other research (Tilden & Grosse) (10) has found that, over time, long-term programmes such as dietary modifications are even more cost-effective than shorter-term interventions.

Further evidence of the cost-effectiveness of vitamin A interventions is available from Chapter 19, on micronutrient deficiency disorders, in the World Bank study (11). Using the current prevalence of deficiencies commonly observed in developing countries and certain assumptions about demographics, death and disability, coverage and effectiveness (75%), the discount rate (3%) and life expectancy (70 years), the discounted cost per DALY gained was calculated based on available costs of micronutrient control programmes. The cost per DALY is estimated at US$ 9 (semi-annual dosage of vitamin A among children 0-5 years) and US$ 29 (vitamin A fortification).
6. CONCLUSION

The evidence summarized above demonstrates the very favourable cost-benefits and cost-utility of the existing interventions available in four disease areas. The following table summarizes the key findings of the evidence quoted.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cost per DALY saved (US$)</th>
<th>Cost-benefit</th>
<th>Economic rate of return</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Bank</td>
<td>15-32</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lumbini</td>
<td>5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Onchocerciasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCP</td>
<td></td>
<td></td>
<td>20%</td>
</tr>
<tr>
<td>APOC</td>
<td></td>
<td></td>
<td>18%</td>
</tr>
<tr>
<td>Trachoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-surgical</td>
<td>3-11</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Surgical</td>
<td>10-59 (HALY)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Childhood blindness (xerophthalmia)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mass-dose capsule</td>
<td>9</td>
<td>2.4-3.4</td>
<td>-</td>
</tr>
<tr>
<td>Fortification</td>
<td>29</td>
<td>6-21</td>
<td>-</td>
</tr>
<tr>
<td>Measles immunization</td>
<td>2-15</td>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

This demonstrates the outstanding returns available from interventions in all of these areas. Obviously, local conditions will dictate the specific returns available to individual programmes, but the effectiveness of the interventions available and the robust nature of the existing evidence point to the tremendous cost-effectiveness of blindness prevention and intervention strategies proposed in the Global Initiative.

There is, of course, still considerable scope for further exploring the economic aspects of blindness prevention measures particularly beyond the calculation of DALY costs.

A.F. Smith (12) has prepared some initial, “back of the envelope”, calculations to demonstrate the huge economic burden imposed by blindness resulting from all conditions (including the four listed above). By making some broadbrush assumptions about the loss of productive economic capacity due to blindness, he concludes that the direct economic cost of global blindness would be equivalent to US$ 25 billion. He believes this could be doubled or tripled if indirect costs were also taken into account, that is, the lost time of carers, rehabilitation costs, etc. These are formidable numbers and, while subject to further refinement, again indicate the considerable economic costs of blindness.
REFERENCES

1. *Benefits and costs of preventing, treating and controlling blindness - A preliminary review and annotated bibliography.* Margaret Thomas, International Centre for Eye Health


3. *Disease control priorities in developing countries.* Jamison et al. (eds), Oxford University Press for the World Bank, 1993


11. *Micronutrient deficiency disorders.* H.M. Levin et al. In: *Disease control priorities in developing countries,* Chapter 19 (see 2 above)

CONTROL OF OTHER CAUSES OF BLINDNESS

Disease: GLAUCOMA

Aim: To control visual loss and reduce the prevalence of blindness from glaucoma.

Background:

1. Glaucoma is becoming an increasingly important cause of blindness. It is responsible for 10%-15% of blindness worldwide, i.e., 5 million people.

2. There are different types of glaucoma. Primary open-angle glaucoma is more common in black populations and angle-closure glaucoma more common in south-east Asian countries.

3. Glaucoma is defined as a level of intraocular pressure (often raised above normal) which damages the optic nerve and causes loss of vision. It can occur at any age, but is more common in people over the age of 40 years.

4. The early diagnosis of glaucoma is difficult, there being no single test or examination which is sufficiently sensitive or specific to be used alone to screen a population for this disease.

5. There is a variety of treatment options, all of which aim to lower the pressure and stop further loss of vision. Treatment cannot restore vision which has already been lost.

6. Glaucoma is a priority disease for further research into the etiology, early diagnosis and best method of control, if prevention of blindness from this disease is to become a reality.

Strategies:

1. To increase awareness among high-risk populations of the need for regular glaucoma examinations.

2. To train eye workers in the diagnosis of glaucoma and to refer patients for treatment before the onset of blindness.

3. To provide treatment and follow-up for patients with glaucoma in order to avoid further loss of vision and blindness. Open-angle glaucoma: The recommended treatment for most patients is an operation. Medical treatment may be indicated in some patients. Angle-closure glaucoma: The recommended treatment is an operation (iridectomy), or an iridotomy using a laser.

4. Further evaluation and research are required to determine the appropriate screening and treatment methods for use in developing countries.
Disease: **DIABETIC RETINOPATHY**

**Aim:** To reduce the prevalence of blindness from diabetic retinopathy.

**Background:**

1. The prevalence of diabetes mellitus varies in different populations according to genetic predisposition and environmental risk factors (particularly diet).

2. Diabetic retinopathy is becoming a major cause of avoidable blindness in middle-aged populations living in urban situations, with an estimated 2.5 million people blind from this disease (7.5% of global blindness).

3. Early treatment with laser applications to the retina can prevent visual loss if given in time.

**Strategies:** Consideration should be given to developing services to prevent diabetic retinopathy in communities where diabetes is responsible for at least 10% of all blindness. The following strategies should be implemented:

1. Promotion of community awareness about diabetes and visual loss.

2. Education of medical practitioners regarding good control of diabetics and the need for annual fundoscopy of all diabetics to detect early retinopathy before the onset of visual loss.

3. Provision of a laser and trained ophthalmologist to provide a diabetic retinopathy treatment service.

Disease: **CORNEAL SCAR**

**Aim:** To reduce the prevalence of blindness from corneal scar.

**Background:**

1. Most of the causes of corneal blindness, such as vitamin A deficiency, measles and trachoma, can be prevented effectively and inexpensively by primary health care measures, for example measles immunization, nutrition education, improved hygiene.

2. However, some corneal conditions, particularly keratoconus and other corneal dystrophies, cannot be prevented. They primarily affect young people and, for these patients, corneal transplantation is the only way of restoring sight.

3. A major limitation to corneal grafting in many countries is the lack of suitable donor material. Corneas can now be preserved in eye banks for up to two weeks following the death of the donor. This permits a single eye bank to provide corneas to many different eye hospitals, some of which may be thousands of kilometres from the eye bank.
4. The results of corneal grafting (penetrating keratoplasty (PKP)) depend upon the following:

(a) The original corneal pathology - some causes of corneal visual loss do badly with PKP (for example dense vascularized corneal scarring) and some do reasonably well (for example keratoconus).

(b) The quality of the donor material - high-quality corneal banks will produce better donors and therefore more chance of success.

(c) The skill of the surgeon.

(d) The compliance of the patient to regular follow-up visits after surgery.

5. Results from developing countries suggest the following:

(a) Corneal grafting for keratoconus and other corneal dystrophies has a good prognosis.

(b) Corneal grafting requires a great deal of commitment on the part of the surgeon and the patients if it is to have any chance of success.

(c) Corneal grafting for scarring resulting from the commonest causes of corneal blindness - such as trachoma, measles, opthalmia neonatorum, etc. - carries a very poor prognosis.

Strategies:

1. To promote the development of corneal grafting in specialized centres which have the staff and the expertise to carry out the surgery and postoperative follow-up.

2. To promote the development of eye banks so that donor material can be made readily available.

3. Priority for corneal grafting should be given to young people with keratoconus or other corneal dystrophies, and to bilaterally blind patients.
OTHER CAUSES OF BLINDNESS

Background: The other major causes of blindness not discussed in the previous sections are:

(a) leprosy;
(b) diseases of the retina;
(c) optic atrophy;
(d) uveitis;
(e) trauma.

Strategies:

1. Identification of the important diseases which cause blindness in any area.
2. Development of a preventive/curative strategy to control these diseases.
3. Provision of service delivery through existing health and eye care services.